611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net
Medical Disorders
Resources
Basic InformationLookupsLatest News
Many U.S. Seniors May Need Better Knee Arthritis CareAfter COVID, Many Americans Are Struck by New Maladies: StudyCataracts: Common, and Easy to TreatThere Are Many Good Reasons for Kids to Get the COVID VaccineBabies Produce Strong Immune Response to Ward Off COVID-19: StudyNovavax's COVID Vaccine Shines in Latest TrialAHA News: U.S. Appears to Lose Ground in Controlling High Blood PressureOdds for Death, Hospital Care Rise When Statins Are StoppedWeight-Loss Surgeries Used Least in U.S. States That Need Them MostObesity Could Raise Odds for 'Long-Haul' COVID SymptomsSmokers, Obese People Need Major Heart Interventions Earlier in LifeOld Age No Bar to Successful Heart Transplant, Study FindsCOVID Antibody Treatment Is Safe, Effective in Transplant PatientsThere Is No 'Healthy Obesity,' Study FindsExpiration Dates on Johnson & Johnson COVID Vaccine ExtendedWill People Really Need a Yearly COVID Booster Vaccine?America Is Losing the War Against DiabetesGene Editing Technique Corrects Sickle Cell Disease in MiceCOVID Vaccines Appear Safe for People With IBDNew Treatment Fights Rare Cases of Vaccine-Linked Blood ClotsWoman Dies From Dengue Fever Acquired in FloridaAstraZeneca COVID Vaccine Tied to Rare Cases of Low Blood PlateletsWhy a COVID Diagnosis Could Cost You Way More Money in 2021New Links Between Poor Sleep, Diabetes and DeathVaccinations More Urgent as Variant That Crippled India Shows Up in the U.S.Think You Can Skip That Annual Physical?  Think AgainReal-World Study Shows Power of Pfizer, Moderna Vaccines to Prevent COVIDDeath Rates Are Rising Across Rural AmericaWhat Diet Is Most Likely to Help Ease Crohn's Disease?'Breakthrough' COVID Infections May Be Common in Vaccinated Transplant PatientsYour Teen's Smartphone Could Be Key to Unhealthy WeightToo Much Caffeine Might Raise Your Odds for GlaucomaPeople of Color Have Twice the Risk of Dying After Brain Injury, Study FindsStudy Pinpoints Cancer Patients at Highest Risk From COVIDMany Existing Drugs Could Be Potent COVID Fighters: StudyAntibiotics Won't Help Fight Lung-Scarring Disease IDF: StudyNew Disabilities Plague Half of COVID Survivors After Hospital DischargeDeclining Vaccination Rates Threaten Biden's July 4 GoalYour Doctor Appointments Might Look Different Post-PandemicPrior COVID Infection May Shield You From Another for at Least 10 MonthsTeens: You Got Your COVID Vaccine, What Now?White House Lists Countries Getting First Batch of Extra COVID VaccinesStrokes Hitting COVID Patients Are More Severe: StudyAverage COVID Hospital Bill for U.S. Seniors Nearly $22,000Deep Brain Stimulation Therapy May Help Parkinson's Patients Long TermNIH Starts Trial Assessing 'Mix & Match' COVID Vaccine ApproachAllergy Treatment Crucial If Your Child Has AsthmaScientists Discover Rare Form of ALS That Can Strike KidsGlobal Warming to Blame for 1 in 3 Heat-Related Deaths WorldwideBlood Sugar Tests Using Sweat, Not Blood? They Could Be on the Way
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Real-World Studies Show Pfizer Vaccine Shields Against COVID Variants

HealthDay News
by By Dennis Thompson HealthDay Reporter
Updated: May 6th 2021

new article illustration

THURSDAY, May 6, 2021 (HealthDay News) -- In two real-world studies, Pfizer's COVID-19 vaccine appears to be standing up well against the challenges posed by more contagious coronavirus variants from Britain and South Africa.

The Pfizer mRNA vaccine showed about 90% documented effectiveness in protecting against infection with the British B.1.1.7 variant and 75% effectiveness against the South African B.1.351 variant, according to numbers out of Qatar, a small Arabian nation located on the Persian Gulf.

The vaccine "was effective against infection and disease in the population of Qatar, despite the B.1.1.7 and B.1.351 variants being predominant within the country," reported researchers from Weill Cornell Medicine-Qatar in Doha, Qatar.

The effectiveness against the variants was lower than the 95% efficacy demonstrated in clinical trial data for which the Pfizer vaccine received emergency use authorization from the U.S. Food and Drug Administration, according to the team led by Laith Abu-Raddad.

"Nevertheless, the reduced protection against infection with the B.1.351 variant did not seem to translate into poor protection against the most severe forms of infection [i.e., those resulting in hospitalization or death], which was robust, at greater than 90%," the Qatar researchers wrote. Their report was published May 5 in the New England Journal of Medicine.

Meanwhile, a second study published the same day in The Lancet medical journal showed that two doses of the Pfizer COVID-19 vaccine provide a high level of protection.

The findings from Israel -- the first nation to report national data on the vaccine -- showed that two doses provide more than 95% protection for people age 16 and older against COVID-19 infection, hospitalization and death.

The study period was from Jan. 24 to April 3, 2021, a time when the dominant strain in Israel was the B.1.1.7 variant first detected in the United Kingdom.

Pfizer vaccine holds its own against variants

A single dose of the vaccine provided 58% protection against infection, 76% against hospitalization and 77% against death, the investigators found.

The differences between the effectiveness of one or two doses highlights the importance of fully vaccinating adults, the researchers said.

The findings also show the public health benefits of a national vaccination program, which was the key driver of a decline in COVID-19 infections in Israel.

"As the country with the highest proportion of its population vaccinated against COVID-19, Israel provides a unique real-world opportunity to determine the effectiveness of the vaccine and to observe wider effects of the vaccination program on public health," said study author Sharon Alroy-Preis, from the Israel Ministry of Health.

"Until this point, no country in the world had described the national public health impact of a nationwide COVID-19 vaccination campaign," she noted in a journal news release. "These insights are hugely important because, while there are still some considerable challenges to overcome, they offer real hope that COVID-19 vaccination will eventually enable us to control the pandemic."

One U.S. expert called the Qatar data "very good news."

"This is another example of the vaccine's value at being protective against COVID-19 infection, even when variant strains are involved," said Dr. David Hirschwerk, attending infectious diseases physician at Northwell Health in Manhasset, N.Y.

By comparison, the estimated effectiveness of the annual flu vaccine usually ranges between 40% and 60%, with some years dipping even lower, according to the U.S. Centers for Disease Control and Prevention.

Breakthrough infections after vaccination were rare

That's because the influenza virus mutates much more readily than the COVID-19 virus, and each year's flu vaccine constitutes an educated guess about which new strains will circulate most widely in the United States.

In the study, genetic testing indicated that about 50% of COVID-19 cases in Qatar between Feb. 23 and March 18 were caused by the South African variant and 45% by the British variant.

As of March 31, breakthrough infections had been recorded in 6,689 Qatar residents who had received one dose of the vaccine, and in 1,616 people who had received two doses.

That's out of the nearly 386,000 people who'd gotten one dose and the more than 265,000 who'd completed the two-dose vaccination series.

Seven deaths from COVID-19 have been recorded among vaccinated persons in Qatar -- five after the first dose and two after the second.

"The study illustrates what many of us have been highlighting for some time: that when it comes to serious disease, hospitalization and death, the major vaccines fare extremely well even in the face of problematic variants like B.1.351," said Dr. Amesh Adalja, a senior scholar with the Johns Hopkins Center for Health Security in Baltimore.

"While virus variants may be able to escape some immunity induced by vaccines, the vaccines are still highly effective at the task they were designed for: taming the virus and removing its ability to kill," Adalja concluded.

Dr. Miriam Smith is chief of infectious diseases at Long Island Jewish Forest Hills in New York City. Reviewing the Qatar findings, she said that "despite a reduction in protection against infection with the B.1.351 variant, the vaccine is effective and should absolutely be encouraged."

And the bigger slice of the world's population that gets vaccinated, the better, Smith added.

"Viruses naturally mutate over time," Smith said, but "increased immunity of the population will have a positive impact on reducing viral transmission and the virus' ability to develop additional variants that could potentially cause resistance vaccine."

More information

The U.S. Centers for Disease Control and Prevention has more on COVID-19 vaccines.

SOURCES: David Hirschwerk, MD, attending physician, Infectious Diseases, Northwell Health, Manhasset, N.Y.; Miriam Smith, MD, chief, Infectious Diseases, Long Island Jewish Forest Hills, New York City; Amesh Adalja, MD, senior scholar, Johns Hopkins Center for Health Security, Baltimore; New England Journal of Medicine, May 5, 2021; The Lancet, May 5, 2021